
    
      Adoptive cell transfer therapy that utilizes an autologous TIL manufacturing progress is
      originally developed by the NCI for the treatment of patients with recurrent, metastatic
      cervical cancer. TILs specific to personalized neo-antigens will be expended in vitro and
      given back to the patients through vein. A total of 20 patients will be enrolled in the
      single-arm, open label, interventional study.
    
  